WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.2 Million Offering

Rhea-AI Summary

bioAffinity Technologies (Nasdaq:BIAF) priced a registered public offering for expected gross proceeds of $3.2 million before fees and expenses.

The deal comprises 4,000,000 shares of common stock (or pre-funded warrants) at $0.80 per share, with closing anticipated around June 18, 2026. WallachBeth Capital is sole placement agent.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Positive

• Raises approximately $3.2 million in gross proceeds before fees
• Registered offering under effective Form S-1 (File No. 333-296764)
• Engages WallachBeth Capital as sole placement agent for the transaction

Negative

• Issuance of 4,000,000 new shares may dilute existing shareholders
• Offering price of $0.80 per share may signal pressure on valuation

News Market Reaction – BIAF

-11.96%

7 alerts

-11.96% News Effect

-13.6% Trough in 4 hr 58 min

-$582K Valuation Impact

$4.28M Market Cap

0.2x Rel. Volume

On the day this news was published, BIAF declined 11.96%, reflecting a significant negative market reaction. Argus tracked a trough of -13.6% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $582K from the company's valuation, bringing the market cap to $4.28M at that time.

Data tracked by StockTitan Argus on the day of publication.

What This Means

The stock dropped -12.0% in the session following this news. A negative reaction despite financing n...

Analysis

The stock dropped -12.0% in the session following this news. A negative reaction despite financing news fits BIAF’s pattern, as prior offerings averaged moves of -16.33% and individual events saw declines up to -38.56%. The current -31.04% drop and volume at 9.32x normal levels suggest investors focused on dilution from the $3.2M stock and pre-funded warrant deal. With shares already below the $2.41 200-day MA and short interest around 15.41%, volatility risk appeared elevated.

Key Figures

Gross proceeds: $3.2 million Shares offered: 4,000,000 shares Offering price per share: $0.80 per share +5 more

8 metrics

Gross proceeds $3.2 million Aggregate gross proceeds from current public offering

Shares offered 4,000,000 shares Common stock (or pre-funded warrants) in current offering

Offering price per share $0.80 per share Purchase price for common stock in offering

Pre-funded warrant price $0.793 per warrant Purchase price per pre-funded warrant in offering

Par value $0.007 per share Par value of common stock underlying offering

Expected closing date June 18, 2026 Expected closing of the public offering

Registration statement Form S-1, File No. 333-296764 SEC registration statement for this offering

Price reaction -31.04% Share price move ahead of / around offering news

Previous Offering Reports

4 past events · Latest: Sep 30 (Negative)

Same Type Pattern 4 events

Date	Event	Sentiment	24h Move	Catalyst
Sep 30	Public offering closing	Negative	-8.9%	Closed $4.8M public offering of common stock and pre-funded warrants.
Sep 30	Offering completion	Negative	-8.9%	Announced completion of $4.8M public offering to raise gross proceeds.
Sep 29	Offering pricing	Negative	-8.9%	Priced $4.8M public offering with common stock or pre-funded warrants.
Sep 29	Offering pricing	Negative	-38.6%	Announced pricing of $4.8M public offering of common stock and warrants.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Past offerings have consistently drawn negative reactions, with all tracked events followed by single- or double-digit percentage declines.

Recent Company History

Over the past year, bioAffinity has repeatedly accessed the capital markets via public offerings, including a $4.8M raise in late September 2025. Those financings, all involving common stock or pre-funded warrants, produced next-day declines between single- and high double-digit percentages. Today’s $3.2M offering continues that pattern of dilution-driven weakness, coming on top of prior capital raises and against a backdrop of a declining share price and elevated trading volumes.

Historical Comparison

-16.3% avg move · In the past, BIAF’s four offering-related headlines saw an average move of -16.33%. Today’s -31.04% ...

offering

-16.3%

Average Historical Move offering

In the past, BIAF’s four offering-related headlines saw an average move of -16.33%. Today’s -31.04% reaction to the new $3.2M deal is notably more severe than prior financing events.

Offering-related news has been recurrent, with prior events in September 2025 and the current June 2026 deal continuing a pattern of equity and pre-funded warrant financings.

Regulatory & Risk Context

Short Interest: 16.97%

Short Interest

16.97% of float

0% 15% 30%+

moderate as of 2026-05-29 Days to cover: 3.02

Key Terms

pre-funded warrants, registration statement on Form S-1, prospectus, placement agent

4 terms

pre-funded warrants financial

"The offering consists of 4,000,000 shares of its common stock, par value $0.007 per share (or pre-funded warrants in lieu thereof)..."

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

registration statement on Form S-1 regulatory

"The securities described above are being offered by the Company pursuant to a registration statement on Form S-1 (File No. 333-296764)..."

A registration statement on Form S-1 is a detailed filing a company submits to the U.S. securities regulator to register new shares for public sale; it includes a plain-language prospectus, financial statements, business description and risk factors. For investors it matters because it provides the official, comprehensive blueprint of the offering — like an owner’s manual — allowing buyers to assess risks, inspect financial health and compare valuation before deciding to invest.

prospectus regulatory

"The offering is being made only by means of a preliminary prospectus and final prospectus that will form a part of the registration statement."

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

placement agent financial

"WallachBeth Capital, LLC is acting as sole placement agent for the offering."

A placement agent is a professional or firm that helps organizations raise money from investors, such as individuals, institutions, or funds. They act like matchmakers, connecting those seeking investments with the right investors and guiding the process to ensure successful funding. For investors, they can provide access to exclusive opportunities and help navigate complex fundraising efforts.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

JERSEY CITY, N.J., June 17, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, priced a Public Offering of securities as described below for aggregate gross proceeds to the Company of $3.2 million, before deducting agent fees and other estimated expenses payable by the company.

The offering consists of 4,000,000 shares of its common stock, par value $0.007 per share (or pre-funded warrants in lieu thereof) at a purchase price of $0.80 per share (or $0.793 per pre-funded warrant). Each pre-funded warrant will be exercisable for one share of common stock and will be immediately exercisable and will expire when exercised in full.

The closing of the offering is expected to occur on or about June 18, 2026, subject to the satisfaction of customary closing conditions.

WallachBeth Capital, LLC is acting as sole placement agent for the offering.

The securities described above are being offered by the Company pursuant to a registration statement on Form S-1 (File No. 333-296764), as amended, previously filed and declared effective by the Securities and Exchange Commission (the "SEC"). This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. The offering is being made only by means of a preliminary prospectus and final prospectus that will form a part of the registration statement. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Electronic copies of the prospectus supplements may be obtained, when available, from WallachBeth Capital, LLC, via email at cap-mkts@wallachbeth.com, by calling +1 (646) 237-8585, or by standard mail at WallachBeth Capital LLC, Attn: Capital Markets, 185 Hudson St., Suite 1410, Jersey City, NJ 07311, USA.

About WallachBeth Capital LLC:

WallachBeth Capital offers a robust range of capital markets and investment banking services to the healthcare community, connecting corporate clients with leading institutions, supporting issuers and investors in achieving their financial goals. The firm's experience includes initial public offerings, follow-on issues, PIPE offerings, and private transactions and ATM's.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company's ability to close the offering when anticipated and the risk factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

View original content:https://www.prnewswire.com/news-releases/wallachbeth-capital-announces-pricing-of-bioaffinity-technologies-3-2-million-offering-302803249.html

SOURCE WallachBeth Capital LLC

FAQ

What did bioAffinity Technologies (BIAF) announce about its June 2026 stock offering?

bioAffinity Technologies announced a registered public offering expected to raise about $3.2 million in gross proceeds. According to bioAffinity Technologies, the deal includes common stock or pre-funded warrants, with WallachBeth Capital acting as sole placement agent under an effective Form S-1 registration.

How many shares are included in the new bioAffinity Technologies (NASDAQ:BIAF) offering and at what price?

The offering includes 4,000,000 shares of common stock, or pre-funded warrants in lieu, priced at $0.80 per share. According to bioAffinity Technologies, each pre-funded warrant costs $0.793, is immediately exercisable for one share, and remains outstanding until fully exercised.

When is the closing date for the bioAffinity Technologies (BIAF) $3.2 million offering?

The closing of the offering is expected on or about June 18, 2026, subject to customary conditions. According to bioAffinity Technologies, completion depends on standard closing requirements typically applied to registered public offerings conducted under an effective Securities and Exchange Commission Form S-1 registration statement.

What type of securities is bioAffinity Technologies (BIAF) issuing in its June 2026 offering?

bioAffinity Technologies is issuing common stock and pre-funded warrants in its June 2026 offering. According to bioAffinity Technologies, each pre-funded warrant is immediately exercisable for one share of common stock and remains outstanding until exercised in full, providing an alternative to directly purchasing shares.

Who is acting as placement agent for the bioAffinity Technologies (BIAF) June 2026 offering?

WallachBeth Capital is serving as sole placement agent for the offering. According to bioAffinity Technologies, WallachBeth Capital is coordinating the transaction, with the securities registered on Form S-1 and the related final prospectus to be filed and available on the SEC website.

How can investors access the prospectus for the bioAffinity Technologies (BIAF) $3.2 million offering?

Investors can access the final prospectus on the SEC website once filed. According to bioAffinity Technologies, electronic copies may also be requested from WallachBeth Capital via email, phone, or standard mail through its Capital Markets group in Jersey City, New Jersey.